Rifampin (rifampicin) is a semisynthetic antibiotic, derived from the rifamycins which are produced by Streptomyces mediterranei. A number of reports have described its use in the treatment of acute gonococcal infection with cure rates varying from 89 to 93 per cent. (Arya, Rao, and Nnochiri, 1971; Ongom, 1971; Panduro, 1971; and Willcox, Morrison, and Cobbold, 1970). In several reports, some of the treatment failures have responded to a second treatment with rifampin. In vitro studies of gonococcal strains have shown minimal inhibitory concentrations of rifampin to be less than 0O4 ,ug./ml., well within the range considered to be attainable in blood and urine after standard dose regimens (Dans, McGehee, Wilcox, and Finland, 1970) .
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Since problems related to rifampin resistance have been met with in other bacterial infections (Atlas and Turck, 1968; Beam, Newberg, Devine, Pierce, and Davies, 1971) , the following study of rifampin resistance in vitro in gonococci was undertaken.
Methods

BACTERIAL STRAINS
Of the thirteen gonococcal strains used, ten were recent isolates from patients attending a local clinic; all were characterized bacteriologically as Neisseria gonorrhoeae. Three other strains (F-62, 7134, 13) (Evans, Artenstein, and Hunter, 1968 cases of gonorrhoea, GCI agar was further supplemented with the inhibitory antibiotic formulation, VCN (BBL). Mueller-Hinton (MH) agar and broth (Difco) were used to cultivate the meningococcal strains, and Eugon broth (BBL) was used as a suspension and dilution medium for both the gonococci and meningococci.
Rifampin used for rifampin-containing media was provided as a powder by the Pitman-Moore Division, Dow Chemical Co., Indianapolis, Indiana. Rifampincontaining GCI and MH selection agars were made, using a freshly prepared rifampin solution diluted so as to attain the desired final agar concentrations.
SELECTION AND ANALYSIS OF RIFAMPIN-RESISTANT MUTANTS
For the gonococci, each strain was heavily seeded onto four GCI agar plates, incubated for 5 to 6 hrs and then harvested using a total of 12 ml. Eugon broth. The harvests were plated in 0-1 ml. amounts onto GCI 0 4 ,ug./ml. rifampin selection agar both directly and after 10-fold concentration. After 48 hrs' incubation the rifampin-resistant colonies were counted and then analysed for resistance to higher levels of rifampin resistance by replication onto GCI agar containing 6-25 and 100 ,ug./ml. rifampin.
Meningococci were grown in MH broth at 37°C. in a waterbath shaker to an optical density of 0-20, using a Coleman Jr. spectrophotometer (equivalent to 5-6 x 108 cells/ml.). The meningococcal broth cultures were plated directly and after 10-fold concentration onto MH-0-4 itg./ml. rifampin selection agar and mutants nalysed for higher levels of rifampin resistance by replication onto MH agar containing higher concentrations of rifampin. Estimates of the viable numbers of each strain applied to selection plates were made by plating serial dilutions of the plate harvests or broth cultures onto appropriate media without rifampin.
Results
Mutation rates for resistance to rifampin were determined for thirteen strains of gonococci. As shown in Table I , mutants resistant to 0 4 ,tg./ml. rifampin appeared at rates varying from 1 x 10-8 to Rifampin resistance of gonococci and meningococci 501 100 .tg./ml., 400 times more rifampin than was present in the original selection medium (Table II) . These data indicate that the selective pressure exerted by a low concentration of rifampin resulted in the single-step selection of mutants resistant to high rifampin concentrations. JA 10 x 10-9 HU 1 5 x 10-9 TO 1 8 x 10 9 CR 2-7 x 10 9 SH 5 2 x 10-9 F62
5 5 x 10-9 DO 5 7 x 10-9 13 8 5 x 10-9 Clinical studies with rifampin have shown the frequent emergence of rifampin-resistant organisms. In the treatment of urinary tract infections, Atlas and Turck (1968) found that rifampin-resistant Escherichia coli, Proteus mirabilis, and Pseudomonas emerged and persisted in the urines of patients during treatment. Recovery of rifampin-resistant tubercle bacilli from a small number of the patients was reported by Vall-Spinoza, Lester, Moulding, Davidson, and McClatchy (1970) .
Perhaps more pertinent to the present study of gonococci is the experience with rifampin in the chemoprophylaxis of meningococcal nasopharyngeal carriers. After the initial report of Deal and Sanders (1969) of the efficacy of rifampin in eradication of the carrier state, a number of larger field studies were undertaken. In each study where post-treatment meningococcal strains were tested for rifampin sensitivity, resistant strains were found to have emerged (Beam and others, 1971; Devine, Johnson, Rhode, Pierce, Hagerman, and Peckinpaugh, 1971; Eickhoff, 1971; Guttler, Counts, Avent and Beaty, 1971; Weidmer, Dunkel, Pettyjohn, Smith, and Leibovitz, 1971) . Indeed, in one study, transmission of rifampin-resistant meningococci was detected (Beam and others, 1971) . However, systemic disease due to such strains did not occur in these limited trials.
On the basis of these experiences and with the knowledge that resistant gonococcal mutants are easily detected in vitro, it seems likely that clinically significant resistance to rifampin can be expected if the drug is employed widely for treatment of gonococcal infections. It appears desirable that any future clinical studies of rifampin therapy of gonorrhoea be designed so that gonococci isolated from treatment failures can be investigated for rifampin resistance. Summary Rifampin-resistant mutants were detected in vitro in thirteen strains of gonococci by selection on agar containing low concentrations of the antibiotic. Mutation rates varying from 1-0 x 10-8 to 8-5 x 10-9 were observed. Many of the mutants were found to be resistant to very high concentrations of rifampin, indicating that the selective pressure exerted by low concentrations of rifampin resulted in the selection of single-step high-concentration resistant mutants. Similar studies of fourteen meningococcal strains showed that resistant mutants occurred at rates up to ten times greater. These results suggest that gonococcal resistance to rifampin is likely to become a clinically significant problem if rifampin therapy comes into wide usage. 
